Company Overview - Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for use in medically supervised settings [2] - The company's lead product candidate, Niyad™, is a lyophilized formulation of nafamostat, currently studied as an anticoagulant for the extracorporeal circuit [2] - Niyad™ has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) [2] Upcoming Events - Talphera management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, scheduled for October 15-17, 2024 [1] - The specific session for Talphera is set for October 16, 2024, at 3:00 PM ET / 12:00 Noon PT [2] - Registered investors will have the opportunity for 1x1 meetings with Talphera management during the summit [1]
Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit